Tucatinib
Metastatic Malignant Neoplasm In The Brain
Explore 101 assets in Metastatic Malignant Neoplasm In The Brain →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Baptist Health South Florida
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05553522CT.gov Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer | — | Terminated | — | — | — |
NCT05673928CT.gov A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) | — | Recruiting | — | — | — |
NCT05323955CT.gov Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib | — | Active Not Recruiting | — | — | — |
NCT04512261CT.gov TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases | — | Withdrawn | — | — | — |
NCT01921335CT.gov ARRY-380 + Trastuzuamab for Breast w/ Brain Mets | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Malignant Neoplasm In The Brain
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tucatinib (this asset) | Baptist Health South Florida | P2 | B · 58 |
| Trastuzumab | Iambic Therapeutics, Inc | P4 | BB |
| Icotinib | Betta Pharmaceuticals Co., Ltd. | P3 | BB |
| Trastuzumab Deruxtecan | Baptist Health South Florida | P4 | BB |
| Copper Cu 64-Dota-Trastuzumab | City of Hope Medical Center | P4 | BB |
| Capecitabine | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Memantine | NRG Oncology | P3 | BB |
| Regorafenib | Neonc Technologies, Inc. | P2 | BB |
| Gefitinib | Alpha Biopharma (Jiangsu) Co., Ltd. | P3 | B |
+42 more in the Metastatic Malignant Neoplasm In The Brain cohort
Other indications for Tucatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BB · 67 |
| Metastatic Neoplasm | — | P2 | B · 63 |
| Invasive Breast Carcinoma | — | P3 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tucatinib in Metastatic Malignant Neoplasm In The Brain. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tucatinib-metastatic-malignant-neoplasm-in-the-brain-94697
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →